Nektar Therapeutics (NKTR) PT Raised to $63 at Evercore ISI; 'Highlights from 4Q earnings call'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Wall St futures pause after AI rally, focus on Mideast tensions
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Nektar Therapeutics (NKTR) PT Raised to $94 at Canaccord Genuity
March 2, 2018 7:24 AM ESTCanaccord Genuity raised its price target on Nektar Therapeutics (NASDAQ: NKTR) to $94.00 (from $80.00) while maintaining a Buy rating.
... MoreMizuho Sees Potential Nektar Therapeutics (NKTR) Takeover by Bristol-Myers Squibb (BMY) This Year
March 2, 2018 6:31 AM ESTMizuho Securities analyst Difei Yang believes there is a possibility of a Nektar Therapeutics (NASDAQ: NKTR) take-out in 2018 and new positive clinical data of NKTR-214 in combo with Bristol-Myers Squibb (NYSE: BMY) Opdivo reinforces their... More
Nektar Therapeutics (NKTR) PT Raised to $103 at Jefferies
March 2, 2018 1:01 AM ESTJefferies raised its price target on Nektar Therapeutics (NASDAQ: NKTR) to $103.00 (from $88.00) while maintaining a Buy rating.
... More